About: Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic
Creator	Ryerson, Christopher Johannson, Kerri Hambly, Nathan Kolb, Martin Assayag, Deborah Fidler, Lee Fisher, Jolene Marcoux, Veronica Morisset, Julie Shapera, Shane Wong, Alyson
Source	Elsevier; Medline; PMC
abstract	Abstract The 2019 coronavirus disease (COVID-19) pandemic caused by the SARS-CoV-2 virus has affected virtually all aspects of patient care. Healthcare systems around the world are trying to simultaneously treat patients with COVID-19 infection, prepare for its long-term impacts, and manage patients with other acute and chronic diseases. There are multiple ways that the COVID-19 pandemic will directly affect patients with fibrotic interstitial lung disease (ILD), particularly given their common risk factors for poor outcomes. Major issues for patients with ILD will include restricted access to key components of the diagnostic process, new uncertainties in the use of common ILD pharmacotherapies, limited ability to monitor both disease severity and the presence of medication adverse effects, and significantly curtailed research activities. The purpose of this review is to summarize how COVID-19 has impacted key components of the diagnosis and management of fibrotic ILD as well as to provide strategies to mitigate these challenges. We further review major obstacles for researchers and identify priority areas for future ILD research related to COVID-19. Our goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks.
has issue date	2020-04-22(xsd:dateTime)
bibo:doi	10.1016/j.chest.2020.04.019
bibo:pmid	32333929
has license	els-covid
sha1sum (hex)	3eb68abc4260b18d82f9bc7854a8919c1914456a
schema:url	https://doi.org/10.1016/j.chest.2020.04.019
resource representing a document's title	Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the COVID-19 pandemic
has PubMed Central identifier	PMC7194738
has PubMed identifier	32333929
schema:publication	Chest
resource representing a document's body	covid:3eb68abc4260b18d82f9bc7854a8919c1914456a#body_text
is schema:about of	named entity 'personal protective equipment' named entity 'PEEP' named entity 'multidisciplinary' named entity 'ACUTE RESPIRATORY DISTRESS SYNDROME' named entity 'RT-PCR' named entity 'FORCED VITAL CAPACITY' named entity 'REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION' named entity 'FVC' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'MERS' named entity 'Middle East respiratory syndrome' named entity 'RT-PCR' named entity 'acute respiratory distress syndrome' named entity 'FVC' named entity 'SARS-CoV-2' named entity 'fibrotic' named entity 'lung biopsy' named entity 'PEEP' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'SARS-CoV-2' named entity 'ARDS' named entity 'PPE' named entity 'COVID' named entity 'positive end-expiratory pressure' named entity 'Middle East respiratory syndrome' named entity 'COVID-19 pandemic' named entity 'interstitial lung disease' named entity 'receptor' named entity 'infection' named entity 'fibrotic' named entity 'immunocompromised patients' named entity 'prednisone' named entity 'pulmonary fibrosis' named entity 'immunomodulatory' named entity 'translational research' named entity 'receptor' named entity 'HRCT' named entity 'mycophenolate mofetil' named entity 'clinical setting' named entity 'primary care' named entity 'infection' named entity 'COVID' named entity 'remdesivir' named entity 'ILD' named entity 'COVID' named entity 'chronic diseases' named entity 'COVID' named entity 'immunosuppression' named entity 'coronavirus test kits' named entity 'COVID' named entity 'fibrotic' named entity 'interstitial lung disease' named entity 'infection' named entity 'ILD' named entity 'Immunosuppressed' named entity 'COVID-19 pandemic' named entity 'intravenous immunoglobulin' named entity 'ILD' named entity 'immunomodulatory' named entity 'azathioprine' named entity 'lung diseases' named entity 'ILD' named entity 'cytokines' named entity 'COVID-19 infection' named entity 'COVID-19 pandemic' named entity 'plasma' named entity 'diagnostic process' named entity 'COVID-19 infection' named entity 'risk factors' named entity 'antifibrotic' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software